New Preclinical Data Demonstrate Favorable Oral Bioavailability, Robust Brain Penetration and Liver Exposure with ...
University of Queensland researchers have developed a drug that activates a hard-to-target immune receptor—a breakthrough ...
Regeneron's Phase III trial investigated cemdisiran and pozelimab as both monotherapies and in combination in gMG.
InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV) The Company is assessing the most efficient ...
EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W ...
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Medicines Agency's (EMA) ...
A European Medicines Agency (EMA) committee recommended pulling the marketing authorization for avacopan (Tavneos) following a review over data integrity concerns in the vasculitis drug's key ...
IIT Kanpur researchers solve mystery of atypical drug target receptor ...
Asianet Newsable on MSN
IIT Kanpur researchers solve mystery of immune receptor C5aR2's function
IIT Kanpur researchers, led by Professor Arun K Shukla, used cryo-EM to uncover the molecular basis of the atypical immune ...
Atherosclerosis is a lipid-driven chronic inflammatory disease that is modulated by innate and adaptive immunity including humoral immunity. Importantly, antibody alterations achieved by genetic means ...
CTx001, a gene therapy for geographic atrophy, received FDA Fast Track Designation, expediting its development and review process. The Opti-GAIN phase 1/2 trial will assess CTx001's safety, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results